Figure 5.
Myelomonocytic cell-specific S100A8 knockout mice were vulnerable to lethal endotoxemia, and exogenous S100A8 supplementation it was protective
Myelomonocytic cell-specific S100A8 knockout (Lyz2cre:S100A8floxed/floxed) mice or S100A8floxed/floxed mice at 10 weeks of age were used for experiments.
(A) The mRNA expression of S100a8 in peritoneal macrophages and the lungs, spleen, pancreas, fat, inguinal lymph nodes, kidneys, and liver (n = 3).
(B) The percentage of Ly6G or F4/80 positive cells in peritoneal cells and the mean fluorescence intensity (MFI) of PE (Ly6G) and FITC (F4/80) staining were analyzed by flow cytometry with anti-Ly6G-PE and anti-F4/80-Alexa488 antibodies (n = 6).
(C) mRNA expression of the indicated inflammatory cytokine and S100 genes in peritoneal macrophages incubated with PBS or LPS (2 μg/mL) for 2 h (n = 3).
(D) mRNA expression of the indicated inflammatory cytokine and S100 genes in peritoneal cells at 4 h after LPS (2 μg/mL) injection (n = 3).
(E) Serum S100A8 levels at 4 h after PBS or LPS (12.5 μg/gBW) injection (n = 3).
(F) The survival rates, (G) body temperature, and (H) blood glucose levels of mice injected with either PBS or S100A8 (0.1 μg/gBW) at 1 h after LPS (12.5 μg/gBW) stimulation were measured at 12, 24, 36, and 48 h (n = 5–8).
All data from three or four independent experiments are represented as the mean ± SEM ∗p < 0.05, ∗∗p < 0.01; ##p < 0.01 vs. Lyz2cre:S100A8floxed/floxed (LPS + S100A8).